| Q36557906 | Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma |
| Q33709656 | Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts |
| Q97652850 | Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma |
| Q42967810 | Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma |
| Q38246965 | Hepatocellular carcinoma: systemic therapies and future perspectives |
| Q39336729 | Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells |
| Q35679527 | Increased expression of 14-3-3β promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma. |
| Q37766798 | Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives |
| Q34040817 | Parsimonious Discovery of Synergistic Drug Combinations |
| Q28534009 | Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway |
| Q64913937 | Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. |
| Q38712735 | Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo |
| Q37031712 | Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives |
| Q39499156 | Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. |
| Q34241371 | Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled |
| Q36560547 | Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells |
| Q39493066 | Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells |
| Q39383689 | Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies |
| Q37438760 | Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin |
| Q36641099 | Vitexicarpin Acts as a Novel Angiogenesis Inhibitor and Its Target Network |